Evaluation of miR-130 family members as circulating biomarkers for the diagnosis of bladder cancer
Affiliations
- PMID: 32761678
- DOI: 10.1002/jcla.23517
Abstract
Objective: Previous research has shown that the miR-130 family is closely related to the occurrence and development of bladder cancer. We hope to use the miR-130 family members as new, non-invasive, and easily detectable biomarkers for bladder cancer.
Methods: We analyzed 428 cases in The Cancer Genome Atlas-Bladder Urothelial Carcinoma database and verified that the miR-130 family members were significantly overexpressed in bladder cancer. A total of 74 bladder cancer patients and 90 controls were enrolled. The relative expression of the miR-130 family in serum was detected using quantitative reverse transcription-polymerase chain reaction. The diagnostic efficacy of the miR-130 family members was determined using the receiver operating characteristic method (ROC), and a diagnostic panel was built using logistic regression. The results of the study were further confirmed in an external validation set of 492 samples from the Gene Expression Omnibus database.
Results: The expression of the miR-130 family members (except for miR-301b-3p) in the serum of bladder cancer patients was higher than that in the controls. The diagnostic capabilities for bladder cancer were 0.847 (miR-130a-3p), 0.762 (miR-130b-3p), and 0.892 (miR-301a-3p). We established a three-miRNA panel with an area under the ROC curve as high as 0.961, indicating that it is a promising clinical diagnostic biomarker of bladder cancer with high sensitivity and specificity.
Conclusion: The expression levels of miR-130 family members in serum can effectively distinguish the bladder cancer patients from healthy controls. This finding will facilitate the clinical diagnosis of bladder cancer.
Keywords: bladder cancer; circulating biomarker; diagnosis; non-invasive detection.
© 2020 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Similar articles
- Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer.Cancer. 2018 Feb 15;124(4):785-796. doi: 10.1002/cncr.31062. Epub 2017 Nov 7.PMID: 29112225 Free PMC article.
- Plasma microRNA Profiles as a Potential Biomarker in Differentiating Adult-Onset Still's Disease From Sepsis.Front Immunol. 2019 Jan 11;9:3099. doi: 10.3389/fimmu.2018.03099. eCollection 2018.PMID: 30687316 Free PMC article.
- Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis.Cancer Med. 2019 Jun;8(6):2810-2822. doi: 10.1002/cam4.2145. Epub 2019 Apr 21.PMID: 31006985 Free PMC article.
- Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis.Biomed Res Int. 2020 Jul 6;2020:9601876. doi: 10.1155/2020/9601876. eCollection 2020.PMID: 32724822 Free PMC article.
- The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review.Oncotarget. 2017 Jul 11;8(28):45060-45071. doi: 10.18632/oncotarget.15023.PMID: 28178677 Free PMC article. Review.
No hay comentarios:
Publicar un comentario